anti-pd1 Lambrolizumab Merck Treatment
FDA giving merck's anti-pd1 'breakthrough therapy' designation
Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma!
I get scanned again May 14th to see how it's working for me. Last scans continued to show shrinkage.
- Posted using BlogPress from my iPhone